Advertiment
The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.
Chronic lymphocytic leukemia is the most common form of leukemia in the United States. It is estimated that 108,437 persons in the USA are living with or are in remission from CLL. Though its cause remains unknown, it is characterized by the proliferation of B lymphocytes that migrate into the lymph nodes, spleen and liver and invade the bone marrow and blood. This can lead to anemia and/or thrombocytopenia (drop in platelet count) and induces an immunocompromised state in patients, thus increasing the risk of severe infections. Chronic lymphocytic leukemia is rare in patients under 55 years (only 11%) and incidence rises rapidly with age above 55 years. The median age at diagnosis is 72 years. Median survival is about 10 years but varies from less than 3 years to a normal life expectancy depending on prognostic factors.
At present, there is no true curative approach in the vast majority of patients with CLL.
About LFB’s anti-CD20
LFB’s anti-CD20 antibody (LFB-R603) is a chimeric recombinant monoclonal antibody directed towards the CD20 antigen expressed on the surface of B cells. The specific glycosylation profile of LFB-R603 gives it powerful ADCC (antibody-dependent cell-mediated cytotoxicity) activity directed against the tumor cells carrying this antigen. This exceptional high cytotoxicity has been demonstrated in non clinical studies performed in vitro and in vivo experimental models. LFB-R603 could be more effective than the reference anti-CD20 antibody, and thus constitute a major breakthrough in the treatment of Chronic Lymphocytic Leukemia. LFB-R603 is currently under study in a phase I/II clinical trial in Europe for this indication. LFB’s recombinant anti-CD20 received orphan drug status for the treatment of CLL in Europe in October 2009.
Source:
LFB
Related Search
Pre Leukemia Life Expectancy,
Leave a Reply
Suggested Posts
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC The recombi a t a ti-CD20 mo oclo al a tibody produced by LFB Biotech ologies received orpha drug status for the treatme t of Chro ic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orpha Products Developme t was gra ted o August 6th, 2010. Chro ic lymphocytic leukemia is the most commo form of leukemia i the U ited States. It is estimated that [...]. Posted August 27th, 2010 | 3:24 pm
New Evidence Strengthens Link Between Opioids And Cancer Growth The recombi a t a ti-CD20 mo oclo al a tibody produced by LFB Biotech ologies received orpha drug status for the treatme t of Chro ic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orpha Products Developme t was gra ted o August 6th, 2010. Chro ic lymphocytic leukemia is the most commo form of leukemia i the U ited States. It is estimated that [...]. Posted August 27th, 2010 | 3:24 pm
Two Cancer-Promoting Pathways Linked In Esophageal Cancer The recombi a t a ti-CD20 mo oclo al a tibody produced by LFB Biotech ologies received orpha drug status for the treatme t of Chro ic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orpha Products Developme t was gra ted o August 6th, 2010. Chro ic lymphocytic leukemia is the most commo form of leukemia i the U ited States. It is estimated that [...]. Posted August 27th, 2010 | 3:24 pm
Using Molecular Analysis To Identify Specific Cancers The recombi a t a ti-CD20 mo oclo al a tibody produced by LFB Biotech ologies received orpha drug status for the treatme t of Chro ic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orpha Products Developme t was gra ted o August 6th, 2010. Chro ic lymphocytic leukemia is the most commo form of leukemia i the U ited States. It is estimated that [...]. Posted August 27th, 2010 | 3:24 pm
Establishing National Standards For Cancer Survivorship Care The recombi a t a ti-CD20 mo oclo al a tibody produced by LFB Biotech ologies received orpha drug status for the treatme t of Chro ic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orpha Products Developme t was gra ted o August 6th, 2010. Chro ic lymphocytic leukemia is the most commo form of leukemia i the U ited States. It is estimated that [...]. Posted August 27th, 2010 | 3:24 pm